Cargando…
A “Double-Locked” and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy
Theranostic agents for concurrent cancer therapy and diagnosis have begun attracting attention as a promising modality. However, accurate imaging and identification remains a great challenge for theranostic agents. Here, we designed and synthesized a novel theranostic agent H6M based on the “double-...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779152/ https://www.ncbi.nlm.nih.gov/pubmed/35056740 http://dx.doi.org/10.3390/molecules27020425 |
_version_ | 1784637501782097920 |
---|---|
author | Luo, Jia Guan, Zongyu Gao, Weijie Wang, Chen Xu, Zhongyuan Meng, Chi Liu, Yun Zhang, Yuquan Guo, Qingsong Ling, Yong |
author_facet | Luo, Jia Guan, Zongyu Gao, Weijie Wang, Chen Xu, Zhongyuan Meng, Chi Liu, Yun Zhang, Yuquan Guo, Qingsong Ling, Yong |
author_sort | Luo, Jia |
collection | PubMed |
description | Theranostic agents for concurrent cancer therapy and diagnosis have begun attracting attention as a promising modality. However, accurate imaging and identification remains a great challenge for theranostic agents. Here, we designed and synthesized a novel theranostic agent H6M based on the “double-locked” strategy by introducing an electron-withdrawing nitro group into 1-position of a pH-responsive 3-amino-β-carboline and further covalently linking the hydroxamic acid group, a zinc-binding group (ZBG), to the 3-position of β-carboline to obtain histone deacetylase (HDAC) inhibitory effect for combined HDAC-targeted therapy. We found that H6M can be specifically reduced under overexpressed nitroreductase (NTR) to produce H6AQ, which emits bright fluorescence at low pH. Notably, H6M demonstrated a selective fluorescence imaging via successive reactions with NTR (first “key”) and pH (second “key”), and precisely identified tumor margins with a high S/N ratio to guide tumor resection. Finally, H6M exerted robust HDAC1/cancer cell inhibitory activities compared with a known HDAC inhibitor SAHA. Therefore, the NTR/pH-activated theranostic agent provided a novel tool for precise diagnosis and efficient tumor therapy. |
format | Online Article Text |
id | pubmed-8779152 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87791522022-01-22 A “Double-Locked” and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy Luo, Jia Guan, Zongyu Gao, Weijie Wang, Chen Xu, Zhongyuan Meng, Chi Liu, Yun Zhang, Yuquan Guo, Qingsong Ling, Yong Molecules Article Theranostic agents for concurrent cancer therapy and diagnosis have begun attracting attention as a promising modality. However, accurate imaging and identification remains a great challenge for theranostic agents. Here, we designed and synthesized a novel theranostic agent H6M based on the “double-locked” strategy by introducing an electron-withdrawing nitro group into 1-position of a pH-responsive 3-amino-β-carboline and further covalently linking the hydroxamic acid group, a zinc-binding group (ZBG), to the 3-position of β-carboline to obtain histone deacetylase (HDAC) inhibitory effect for combined HDAC-targeted therapy. We found that H6M can be specifically reduced under overexpressed nitroreductase (NTR) to produce H6AQ, which emits bright fluorescence at low pH. Notably, H6M demonstrated a selective fluorescence imaging via successive reactions with NTR (first “key”) and pH (second “key”), and precisely identified tumor margins with a high S/N ratio to guide tumor resection. Finally, H6M exerted robust HDAC1/cancer cell inhibitory activities compared with a known HDAC inhibitor SAHA. Therefore, the NTR/pH-activated theranostic agent provided a novel tool for precise diagnosis and efficient tumor therapy. MDPI 2022-01-10 /pmc/articles/PMC8779152/ /pubmed/35056740 http://dx.doi.org/10.3390/molecules27020425 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Luo, Jia Guan, Zongyu Gao, Weijie Wang, Chen Xu, Zhongyuan Meng, Chi Liu, Yun Zhang, Yuquan Guo, Qingsong Ling, Yong A “Double-Locked” and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy |
title | A “Double-Locked” and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy |
title_full | A “Double-Locked” and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy |
title_fullStr | A “Double-Locked” and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy |
title_full_unstemmed | A “Double-Locked” and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy |
title_short | A “Double-Locked” and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy |
title_sort | “double-locked” and enzyme/ph-activated theranostic agent for accurate tumor imaging and therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779152/ https://www.ncbi.nlm.nih.gov/pubmed/35056740 http://dx.doi.org/10.3390/molecules27020425 |
work_keys_str_mv | AT luojia adoublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT guanzongyu adoublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT gaoweijie adoublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT wangchen adoublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT xuzhongyuan adoublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT mengchi adoublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT liuyun adoublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT zhangyuquan adoublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT guoqingsong adoublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT lingyong adoublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT luojia doublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT guanzongyu doublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT gaoweijie doublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT wangchen doublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT xuzhongyuan doublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT mengchi doublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT liuyun doublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT zhangyuquan doublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT guoqingsong doublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy AT lingyong doublelockedandenzymephactivatedtheranosticagentforaccuratetumorimagingandtherapy |